Protagonist Therapeutics (PTGX) PTG-300 Data is Misunderstood, Nomura Reiterates $29 PT

Go back to Protagonist Therapeutics (PTGX) PTG-300 Data is Misunderstood, Nomura Reiterates $29 PT

Protagonist Therapeutics (PTGX) Halted on LUDP, Up 59%

December 4, 2019 9:47 AM EST

Protagonist Therapeutics (NASDAQ: PTGX) Halted on LUDP, Up 59%

... More